Revive Therapeutics Ltd (CVE:RVV) shares rose 25% during trading on Tuesday . The stock traded as high as C$0.13 and last traded at C$0.13. Approximately 189,800 shares traded hands during trading, an increase of 81% from the average daily volume of 104,708 shares. The stock had previously closed at C$0.10.
The company has a market capitalization of $5.84 million and a P/E ratio of -3.45.
Revive Therapeutics (CVE:RVV) last issued its earnings results on Wednesday, November 28th. The company reported C($0.01) EPS for the quarter.
COPYRIGHT VIOLATION NOTICE: This article was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this article can be viewed at https://www.tickerreport.com/banking-finance/4146162/revive-therapeutics-rvv-stock-price-up-25.html.
Revive Therapeutics Ltd. develops and commercializes cannabinoid-based products in Canada. The company develops REV-002, a bucillamine that has completed Phase II-A clinical studies for the treatment of acute gout flares. Its product pipeline also includes REV-004, a bucillamine for the treatment of cystinurial.
Further Reading: How to Calculate Compound Annual Growth Rate (CAGR)
Receive News & Ratings for Revive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.